Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions

Prospective Randomized Study of Sarpogrelate Versus Clopidogrel-based Dual Antiplatelet Therapies in Patients Undergoing Femoropopliteal Arterial Endovascular Interventions

Background:. Sarpogrelate is a selective 5-hydroxytryptamine (5-HT) receptor subtype 2A antagonist which blocks 5-HT induced platelet aggregation and proliferation of vascular smooth muscle cells. We compared the efficacy of sarpogrelate-based dual antiplatelet therapies for the prevention of resten...

Full description

Bibliographic Details
Main Authors:	Yue-Xin Chen, Wen-Da Wang, Xiao-Jun Song, Yong-Quan Gu, Hong-Yan Tian, He-Jie Hu, Ji-Chun Zhao, Xiao-Qiang Li, Chang-Wei Liu
Format:	Article
Language:	English
Published:	Wolters Kluwer 2015-06-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.4103/0366-6999.158285

Similar Items

A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention
by: Ahram Han, et al.
Published: (2023-02-01)

Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery
by: Jianyu Qu, et al.
Published: (2021-06-01)

Clinical Outcomes after Endovascular Revascularisation of the Femoropopliteal Arterial Segment in Patients with Anticoagulant versus Antiplatelet Therapy: A Single-Centre Retrospective Cohort Study
by: Kevin Pelicon, et al.
Published: (2022-06-01)

Antiplatelet Therapy of Cilostazol or Sarpogrelate with Aspirin and Clopidogrel after Percutaneous Coronary Intervention: A Retrospective Cohort Study Using the Korean National Health Insurance Claim Database.
by: Yoojin Noh, et al.
Published: (2016-01-01)

Algorithm of Femoropopliteal Endovascular Treatment
by: Maxime Dubosq, et al.
Published: (2022-09-01)

Popliteal access for endovascular procedures in femoropopliteal artery occlusive disease
by: Seyhan Yilmaz, et al.
Published: (2023-09-01)

Clopidogrel Resistance in Patients With Stroke Recurrence Under Single or Dual Antiplatelet Treatment
by: Hyun Goo Kang, et al.
Published: (2021-08-01)

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
by: V. A. Sulimov, et al.
Published: (2015-12-01)

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
by: V. A. Sulimov, et al.
Published: (2015-12-01)

Long-Term Outcome of Bypass Surgery versus Endovascular Revascularization in Long Femoropopliteal Lesions
by: Michaela Kluckner, et al.
Published: (2023-05-01)

Dual versus triple antiplatelet therapy in patients with acute coronary syndrome undergoing coronary artery stenting
by: Y.P. Sharma, et al.
Published: (2015-12-01)

Short vs prolonged dual antiplatelet treatment upon endovascular stenting of peripheral arteries
by: Kronlage M, et al.
Published: (2017-10-01)

ASSOCIATION BETWEEN SMOKING AND THE ANTIPLATELET EFFECT OF CLOPIDOGREL
by: K. Yu. Lukianets, et al.
Published: (2020-10-01)

Short-Term Clinical Outcomes of Single Versus Dual Antiplatelet Therapy after Infrainguinal Endovascular Treatment for Peripheral Arterial Disease
by: Jetty Ipema, et al.
Published: (2020-10-01)

Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
by: Pepinghege Fenena, et al.
Published: (2011-01-01)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
by: Viviana Laredo, et al.
Published: (2020-05-01)

Aspirination of α-Aminoalcohol (Sarpogrelate M1)
by: Sunhwa Park, et al.
Published: (2016-08-01)

Modern Antiplatelet Therapy: When Is Clopidogrel the Right Choice?
by: Kendrick Shunk, et al.
Published: (2018-06-01)

Mapping the antiplatelet effects of clopidogrel and aspirin by modified thromboelastography
by: Hemlata, et al.
Published: (2013-01-01)

Single versus dual antiplatelet therapy following peripheral arterial endovascular intervention for chronic limb threatening ischaemia: Retrospective cohort study.
by: Natasha Chinai, et al.
Published: (2020-01-01)

Three-Year Patency Results following Endovascular Transvenous Femoropopliteal Bypass
by: Roberts Rumba, et al.
Published: (2023-02-01)

Predictive value of auscultation of femoropopliteal arteries
by: Carla Kaufmann, et al.
Published: (2013-02-01)

Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction
by: Jong-Shiuan Yeh, et al.
Published: (2023-03-01)

Half‐Dose (45 mg Twice Daily) Ticagrelor Versus Clopidogrel in Neuroendovascular Dual Antiplatelet Therapy: A Single‐Center Cohort Study
by: Tapan Mehta, et al.
Published: (2023-01-01)

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics
by: Amin, Arwa M., et al.
Published: (2017)

Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV
by: Emanuela Marcantoni, PhD, et al.
Published: (2022-11-01)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
by: Satoshi Niijima, et al.
Published: (2018-03-01)

Results of Repeated Open and Endovascular Interventions in Patients with Occlusion of Autovenous Femoropopliteal Bypass
by: Michael Chernyavsky, et al.
Published: (2022-01-01)

The Effect of Severe Femoropopliteal Arterial Calcification on the Treatment Outcome of Femoropopliteal Intervention in Patients with Ischemic Tissue Loss
by: Hyun Yong Lee, et al.
Published: (2020-06-01)

Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice.
by: Kyung-Yeon Park, et al.
Published: (2016-01-01)

Risk Factors of Amputation in Lower Extremity Trauma with Combined Femoropopliteal Arterial Injury
by: JeaHwan Kim, et al.
Published: (2019-03-01)

The Personalization of Clopidogrel Antiplatelet Therapy in Coronary Artery Disease Patients using Pharmacometabonomics, Pharmacogenetics and Platelets Function Testing
by: Mostafa, Arwa Mohamed Amin
Published: (2016)

Influence of rabeprazole and famotidine on pharmacodynamic profile of dual antiplatelet therapy in clopidogrel-sensitive patients: The randomized, prospective, PROTECT trial
by: Jong-Hwa Ahn, et al.
Published: (2020-04-01)

Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis
by: Zhe Wang, et al.
Published: (2020-03-01)

Safety of Intravenous Cangrelor Versus Dual Oral Antiplatelet Loading Therapy in Endovascular Treatment of Tandem Lesions: An Observational Cohort Study
by: Aaron Rodriguez‐Calienes, et al.
Published: (2023-11-01)

Restenosis of the femoropopliteal artery after percutaneous transluminal angioplasty
by: Vladka Salapura, et al.
Published: (2014-05-01)

ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY?
by: S. J. Martsevich
Published: (2016-01-01)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
by: Jan Kiebist, et al.
Published: (2021-09-01)

Current views on antiplatelet therapy in acute coronary syndrome patients: the place of clopidogrel
by: O. O. Shakhmatova
Published: (2022-06-01)

The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel
by: Woong Gil Choi, et al.
Published: (2021-03-01)